Precision BioSciences stock trades quietly amid lack of fresh catalysts

Published on 09/19/2026 at 15:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Precision BioSciences stock shows no major move as of mid September 2026, with recent fundamentals still defining the picture. The shares remain a small cap biotech play focused on gene editing and immuno-oncology.

DTIL, US74019P1084, Illustration mit AI erstellt.

Precision BioSciences stock (ISIN US74019P1084) remains a micro cap biotech name with no major price swing or new company specific catalyst evident as of mid September 2026, leaving recent fundamentals and its pipeline as the main anchors for investor sentiment.

Gene editing focus and recent fundamentals

Precision BioSciences is a biotechnology company that develops gene editing based therapies and immuno-oncology products using its proprietary ARCUS genome editing platform, targeting indications such as hematologic malignancies and genetic liver diseases.

The most recently reported financial figures for Precision BioSciences come from its latest quarterly or annual filings, which show typical small cap biotech dynamics: limited revenue from collaborations or early product sales and continued operating losses as the company invests in research and development; these figures, while important for understanding cash burn and runway, remain within the usual range for pre commercial biotech companies and are used by investors mainly to gauge how long Precision BioSciences can fund its pipeline before needing additional capital.

Stock characteristics for retail investors

As of September 19, 2026, Precision BioSciences stock continues to trade on Nasdaq in United States dollars, with a relatively low market capitalization that places it firmly in the micro cap category and implies higher volatility and liquidity risk compared with larger biotech peers.

Over the past year, Precision BioSciences shares have traded within a wide 52 week range typical for speculative biotechnology names, reflecting shifting expectations around clinical trial progress, partnership prospects and financing conditions; for many retail investors, this means that position sizing and risk management are crucial when dealing with a stock that can move significantly on trial readouts or capital markets decisions.

Closing price context and investor view

On Nasdaq, Precision BioSciences stock most recently closed at a level that leaves it well below the heights reached during earlier phases of optimism about gene editing, underscoring how sentiment in the sector has cooled and how concrete clinical and commercial milestones will be needed to rekindle broader interest in the shares.